Procept Biorobotics (PRCT) Stock Price

Procept Biorobotics Price

NASDAQ·CLOSED
18.10USD+0.16 (+0.86 %)
Market closed

Revenue has compounded at 95.5% per year over the past 6 years to 304.47 M USD. Procept Biorobotics's net margin stands at -31.4%, up from -208.8% several years earlier. Analysts set a median price target of 52.02 USD, implying 187.4% above the current price. Of 20 analysts, 16 rate the stock a buy — an overall Buy consensus. The stock trades about 3% above its 52-week low.

Procept Biorobotics stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Procept Biorobotics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Procept Biorobotics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Procept Biorobotics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Procept Biorobotics Stock Price History
DateProcept Biorobotics Price
7/29/202618.10 USD
7/27/202617.94 USD
7/23/202617.55 USD
7/22/202617.70 USD
7/21/202618.52 USD
7/20/202619.22 USD
7/17/202619.22 USD
7/16/202619.20 USD
7/15/202619.15 USD
7/14/202619.31 USD
7/13/202621.29 USD
7/10/202620.89 USD
7/9/202619.75 USD
7/8/202620.73 USD
7/7/202621.03 USD
7/6/202620.52 USD
7/2/202621.03 USD
7/1/202623.47 USD
6/30/202622.58 USD
6/29/202622.38 USD
6/26/202622.56 USD
6/25/202621.49 USD
6/24/202620.85 USD
6/23/202620.60 USD
6/22/202621.52 USD
6/18/202621.02 USD
6/17/202621.52 USD
6/16/202622.19 USD
6/15/202623.54 USD
6/12/202626.22 USD
6/11/202626.93 USD
6/10/202629.28 USD
6/9/202628.78 USD
6/8/202628.35 USD
6/5/202627.16 USD
6/4/202626.89 USD
6/3/202626.17 USD
6/2/202626.43 USD
6/1/202628.44 USD
5/29/202626.84 USD
5/28/202626.65 USD
5/27/202626.35 USD
5/26/202627.77 USD
5/22/202628.72 USD
5/21/202628.76 USD
5/20/202627.04 USD
5/19/202625.91 USD
5/18/202626.01 USD
5/15/202626.12 USD
5/14/202626.38 USD
5/13/202625.70 USD
5/12/202628.69 USD
5/11/202626.45 USD
5/8/202625.40 USD
5/7/202625.44 USD
5/6/202624.80 USD
5/5/202625.18 USD
5/4/202624.83 USD
5/1/202624.63 USD
4/30/202624.04 USD
4/29/202621.71 USD
4/28/202623.03 USD
4/27/202624.09 USD
4/24/202624.36 USD
4/23/202624.24 USD
4/22/202625.11 USD
4/21/202624.76 USD
4/20/202625.73 USD
4/17/202625.14 USD
4/16/202624.52 USD
4/15/202625.67 USD
4/14/202624.59 USD
4/13/202623.46 USD
4/10/202623.20 USD
4/9/202623.27 USD
4/8/202623.87 USD
4/7/202623.19 USD
4/6/202623.78 USD
4/2/202625.12 USD
4/1/202625.36 USD
3/31/202625.01 USD
3/30/202625.55 USD
3/27/202626.36 USD
3/26/202625.07 USD
3/25/202624.94 USD
3/24/202625.10 USD
3/23/202626.02 USD
3/20/202625.79 USD
3/19/202625.68 USD
3/18/202626.17 USD
3/17/202627.36 USD
3/16/202627.99 USD
3/13/202627.13 USD
3/12/202626.12 USD
3/11/202627.80 USD
3/10/202624.17 USD
3/9/202625.26 USD
3/6/202624.22 USD
3/5/202625.35 USD
3/4/202626.56 USD
3/3/202626.26 USD
3/2/202625.90 USD
2/27/202622.69 USD
2/26/202623.63 USD
2/25/202627.84 USD
2/24/202627.26 USD
2/23/202627.36 USD
2/20/202627.27 USD
2/19/202626.76 USD
2/18/202627.72 USD
2/17/202628.12 USD
2/13/202627.79 USD
2/12/202628.09 USD
2/11/202628.50 USD
2/10/202629.95 USD
2/9/202629.21 USD
2/6/202628.74 USD
2/5/202627.40 USD
2/4/202628.93 USD
2/3/202629.19 USD
2/2/202629.14 USD
1/30/202628.96 USD
1/29/202629.12 USD
1/28/202630.02 USD
1/27/202630.78 USD
1/26/202629.61 USD
1/23/202629.13 USD
1/22/202630.73 USD
1/21/202630.95 USD
1/20/202630.31 USD
1/16/202630.38 USD
1/15/202630.50 USD
1/14/202631.37 USD
1/13/202630.58 USD
1/12/202631.33 USD
1/9/202632.83 USD
1/8/202634.48 USD
1/7/202633.92 USD
1/6/202634.71 USD
1/5/202633.12 USD
1/2/202630.76 USD
12/31/202531.46 USD
12/30/202531.53 USD
12/29/202532.15 USD
12/26/202532.41 USD
12/24/202532.88 USD
12/23/202532.72 USD
12/22/202534.26 USD
12/19/202532.06 USD
12/18/202532.73 USD
12/17/202533.78 USD
12/16/202535.66 USD
12/15/202536.10 USD
12/12/202535.99 USD
12/11/202536.03 USD
12/10/202535.71 USD
12/9/202535.00 USD
12/8/202534.03 USD
12/5/202535.86 USD
12/4/202535.43 USD
12/3/202533.18 USD
12/2/202529.53 USD
12/1/202530.41 USD
11/28/202531.68 USD
11/26/202531.68 USD
11/25/202532.27 USD
11/24/202530.01 USD
11/21/202529.86 USD
11/20/202527.89 USD
11/19/202527.93 USD
11/18/202528.40 USD
11/17/202529.08 USD
11/14/202529.69 USD
11/13/202530.42 USD
11/12/202530.77 USD
11/11/202531.34 USD
11/10/202530.94 USD
11/7/202531.92 USD
11/6/202531.30 USD
11/5/202531.61 USD
11/4/202535.02 USD
11/3/202534.51 USD
10/31/202534.03 USD
10/30/202534.38 USD
10/29/202535.93 USD
10/28/202536.95 USD
10/27/202536.35 USD
10/24/202534.99 USD
10/23/202534.62 USD
10/22/202535.10 USD
10/21/202534.61 USD
10/20/202534.72 USD
10/17/202532.97 USD
10/16/202533.94 USD
10/15/202533.76 USD
10/14/202533.92 USD
10/13/202533.00 USD
10/10/202532.92 USD
10/9/202534.83 USD
10/8/202534.75 USD
10/7/202534.61 USD
10/6/202535.24 USD
10/3/202535.97 USD
10/2/202534.80 USD
10/1/202534.73 USD
9/30/202535.69 USD
9/29/202536.49 USD
9/26/202536.66 USD
9/25/202537.02 USD
9/24/202537.65 USD
9/23/202539.15 USD
9/22/202538.46 USD
9/19/202537.39 USD
9/18/202538.03 USD
9/17/202537.28 USD
9/16/202539.57 USD
9/15/202538.00 USD
9/12/202537.14 USD
9/11/202538.64 USD
9/10/202537.50 USD
9/9/202539.52 USD
9/8/202538.92 USD
9/5/202540.68 USD
9/4/202538.34 USD
9/3/202537.84 USD
9/2/202539.57 USD
8/29/202540.17 USD
8/28/202540.34 USD
8/27/202540.80 USD
8/26/202540.52 USD
8/25/202539.31 USD
8/22/202541.23 USD
8/21/202539.35 USD
8/20/202539.38 USD
8/19/202539.72 USD
8/18/202540.71 USD
8/15/202541.59 USD
8/14/202540.12 USD
8/13/202540.38 USD
8/12/202538.60 USD
8/11/202538.77 USD
8/8/202538.41 USD
8/7/202539.59 USD
8/6/202545.69 USD
8/5/202548.12 USD
8/4/202549.60 USD
8/1/202549.96 USD
7/31/202548.51 USD
7/30/202551.35 USD
Access this data via the Eulerpool API
Get Free API Key

Procept Biorobotics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
132.46 M USD
-109.17 M USD
-105.90 M USD
Jan 1, 2024
220.31 M USD
-96.61 M USD
-91.41 M USD
Jan 1, 2025
304.47 M USD
-103.86 M USD
-95.57 M USD
Jan 1, 2026 (e)
397.47 M USD
185.03 M USD
-85.40 M USD
Jan 1, 2027 (e)
490.49 M USD
228.34 M USD
-49.64 M USD
Jan 1, 2028 (e)
587.90 M USD
273.69 M USD
-33.29 M USD
Jan 1, 2029 (e)
681.61 M USD
317.31 M USD
-10.00 M USD
Jan 1, 2030 (e)
794.90 M USD
370.05 M USD
35.55 M USD

Procept Biorobotics Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 30, 2026, 3:38 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
20192020202120222023202420252026e2027e2028e2029e2030e
6.007.0034.0075.00136.00224.00308.00397.00490.00587.00681.00794.00
–16.67385.71120.5981.3364.7137.5028.9023.4319.8016.0116.59
-16.67-14.2944.1249.3352.2161.1663.6463.6463.6463.6463.6463.64
-1.00-1.0015.0037.0071.00137.00196.00252.64311.82373.55433.36505.27
-43.00-47.00-54.00-84.00-109.00-96.00-103.00185.00228.00273.00317.00370.00
-716.67-671.43-158.82-112.00-80.15-42.86-33.4446.6046.5346.5146.5546.60
-41.00-53.00-59.00-87.00-105.00-91.00-95.00-85.00-49.00-33.00-9.0035.00
–29.2711.3247.4620.69-13.334.40-10.53-42.35-32.65-72.73-488.89
56.0735.1443.5444.7750.5953.8456.0756.0756.0756.0756.0756.07
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Procept Biorobotics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Procept Biorobotics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Procept Biorobotics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Procept Biorobotics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Procept Biorobotics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Procept Biorobotics stock margins

The Procept Biorobotics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Procept Biorobotics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Procept Biorobotics.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
55.35 %
-188.97 %
-208.82 %
Jan 1, 2022
53.11 %
-120.96 %
-124.81 %
Jan 1, 2023
53.64 %
-82.42 %
-79.95 %
Jan 1, 2024
62.23 %
-43.85 %
-41.49 %
Jan 1, 2025
64.45 %
-34.11 %
-31.39 %
Jan 1, 2026 (e)
64.45 %
46.55 %
-21.49 %
Jan 1, 2027 (e)
64.45 %
46.55 %
-10.12 %
Jan 1, 2028 (e)
64.45 %
46.55 %
-5.66 %

Procept Biorobotics Stock Revenue, EBIT, Earnings per Share

The Procept Biorobotics earnings per share therefore indicates how much revenue Procept Biorobotics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.66 USD
-1.24 USD
-1.37 USD
Jan 1, 2022
1.56 USD
-1.89 USD
-1.95 USD
Jan 1, 2023
2.62 USD
-2.16 USD
-2.09 USD
Jan 1, 2024
4.09 USD
-1.79 USD
-1.70 USD
Jan 1, 2025
5.43 USD
-1.85 USD
-1.70 USD
Jan 1, 2026 (e)
7.16 USD
3.30 USD
-1.54 USD
Jan 1, 2027 (e)
8.83 USD
4.07 USD
-0.89 USD
Jan 1, 2028 (e)
10.58 USD
4.88 USD
-0.60 USD

Procept Biorobotics business model & stock analysis

PROCEPT BioRobotics Corp (PROCEPT) is a California-based medical technology company specializing in the development of robotic technologies for urological surgery. History: PROCEPT was founded in 2013 by Dr. Chin and his group at Johns Hopkins University School of Medicine. They developed a novel technology that had the potential to revolutionize the treatment of prostate cancer. PROCEPT used a robust Intuitive Surgical platform and developed a novel tissue classification technology that allows surgeons to operate with accuracy and safety. The first system, called AquaBeam®, was approved by the US Food and Drug Administration (FDA) in 2018 and has since been in use in Europe and the US. Business: PROCEPT aims to improve urological surgery through the use of robotic technologies, thereby increasing patient safety and care. The company focuses on the development and commercialization of robotic systems for the treatment of prostate cancer and other urological diseases. Products: PROCEPT has developed Aquablation®, a robotic system for the treatment of prostate cancer. It is a minimally invasive technology that uses high-precision waterjet cutting (accuracy reduced to millimeters) to remove cancerous tissue quickly, effectively, and accurately. The technology can also be used in surgical procedures on the bladder, urethra, and other urological organs. Divisions: PROCEPT has a broad portfolio of services and products in the field of urological surgery. The AquaBeam® technology is the first system developed to treat malignant prostate tumors using robotic technologies. The technology is used in hospitals, clinics, and medical facilities worldwide. In addition, PROCEPT offers training and support for surgeons and medical personnel. Conclusion: PROCEPT BioRobotics Corp is an emerging medical technology company specializing in robotics-based urological surgery. The AquaBeam® technology is an innovative, robotic technology for the treatment of prostate cancer. The company is on its way to revolutionizing urological surgery and making a significant contribution to improving healthcare.

Procept Biorobotics SWOT Analysis

Strengths

PROCEPT BioRobotics Corp possesses several strengths that contribute to its success in the market. These strengths include:

  • Advanced Technology: PROCEPT BioRobotics Corp utilizes state-of-the-art robotic systems in its medical procedures, providing exceptional precision and accuracy.
  • Unique Solution: The company's Aquablation therapy system is a unique, innovative approach for the treatment of benign prostatic hyperplasia (BPH), offering potential advantages over traditional surgical methods.
  • Talented Team: PROCEPT BioRobotics Corp boasts a highly skilled and experienced team of researchers, engineers, and medical professionals, driving continuous product improvement and development.
  • Market Reputation: The company has built a strong reputation in the medical industry for its groundbreaking technology and successful patient outcomes.

Weaknesses

Despite its strengths, PROCEPT BioRobotics Corp faces certain weaknesses that may pose challenges to its growth and market position. These weaknesses include:

  • Limited Market Exposure: The company's Aquablation therapy is a relatively new treatment option, limiting its market reach to certain regions and healthcare facilities.
  • High Costs: The robotic systems used by PROCEPT BioRobotics Corp can be expensive, making it less accessible to smaller healthcare providers or regions with limited financial resources.
  • Competition: The medical technology landscape is highly competitive, with the presence of established players and emerging startups, which may affect the company's market share.

Opportunities

PROCEPT BioRobotics Corp can take advantage of various opportunities to enhance its market presence and expand its operations. These opportunities include:

  • Global Market Expansion: By seeking regulatory approvals in additional countries and forming strategic partnerships with international distributors, the company can tap into new geographical markets.
  • Product Diversification: Developing and introducing new robotic systems or expanding Aquablation therapy for other medical conditions could broaden PROCEPT BioRobotics Corp's product portfolio.
  • Medical Industry Growth: The rising prevalence of BPH and other urological conditions presents an opportunity for the company to address a growing market demand.

Threats

Several threats exist that may impact the success and growth of PROCEPT BioRobotics Corp. These threats include:

  • Regulatory Challenges: Meeting stringent regulatory requirements and obtaining necessary approvals can be time-consuming and costly, potentially delaying market entry and expansion.
  • Changing Healthcare Policies: Shifts in healthcare policies or reimbursement systems could impact the financial viability and adoption of the company's products and therapies.
  • Technological Advancements: Competitors may introduce newer and more advanced robotic systems or alternative therapies that could challenge PROCEPT BioRobotics Corp's market position.

Procept Biorobotics Segments

Procept Biorobotics Revenue by Segment

  • 3 Years

  • Max

Handpieces and other consumables
System sales and rentals
Service
Details
Date
Handpieces and other consumables
System sales and rentals
Service
Jan 1, 2021
2.63 M USD
2.49 M USD
398,000.00 USD
Jan 1, 2022
3.27 M USD
3.20 M USD
772,000.00 USD
Jan 1, 2023
5.47 M USD
5.29 M USD
1.13 M USD
Jan 1, 2024
10.91 M USD
11.69 M USD
1.43 M USD
Jan 1, 2025
21.78 M USD
13.13 M USD
2.77 M USD

Procept Biorobotics Revenue by Region

  • 3 Years

  • Max

United States
Other Countries
Outside of U.S
Details
Date
United States
Other Countries
Outside of U.S
Jan 1, 2021
28.95 M USD
0.00 USD
5.53 M USD
Jan 1, 2022
67.77 M USD
0.00 USD
7.25 M USD
Jan 1, 2023
124.30 M USD
0.00 USD
11.89 M USD
Jan 1, 2024
200.47 M USD
0.00 USD
24.03 M USD
Jan 1, 2025
270.38 M USD
37.68 M USD
0.00 USD

Procept Biorobotics Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Procept Biorobotics historical P/E ratio, EBIT multiple, and P/S ratio

Procept Biorobotics annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Procept Biorobotics shares outstanding

The number of shares of Procept Biorobotics was 56.07 M in 2025. This indicates how many shares Procept Biorobotics is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
43.54 M Stocks
Jan 1, 2022
44.77 M Stocks
Jan 1, 2023
50.59 M Stocks
Jan 1, 2024
53.84 M Stocks
Jan 1, 2025
56.07 M Stocks
Jan 1, 2026 (e)
56.07 M Stocks
Jan 1, 2027 (e)
56.07 M Stocks
Jan 1, 2028 (e)
56.07 M Stocks

Current Procept Biorobotics forecasts and price targets in July 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy80.00 % (16)
Hold20.00 % (4)
Sell0.00 % (0)
12M Price Target
52.02
Last Price
18.10
Currency
USD
12M Return Potential
187.40 %
LTM Return
0 %

Procept Biorobotics Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
8/4/2026-0.47USD94.63 MUSD2026 Q2
7/30/2026-0.47USD94.63 MUSD2026 Q2
4/30/2026-0.57USD82.12 MUSD2026 Q1
4/29/2026-0.57USD82.12 MUSD2026 Q1
4/22/2026-0.57USD82.12 MUSD2026 Q1
2/24/2026-0.33USD96.02 MUSD2025 Q4
4/25/2024-0.52USD41.35 MUSD2024 Q1
2/26/2024-0.44USD41.73 MUSD2023 Q4

EESG©

Eulerpool ESG Scorecard© for the Procept Biorobotics stock

50/100
27
Environment
68
Social
56
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees41
Percentage of women in management—
Percentage of Asian employees36
Share of Asian management—
Percentage of Hispanic/Latino employees14
Hispano/Latino Management share—
Percentage of Black employees4
Black Management Share—
Percentage of white employees46
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Procept Biorobotics shareholder structure

% Name
9.34100%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
8.30209%
Fidelity Management & Research Company LLC
Fidelity Management & Research Company LLC
6.82019%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
6.09503%
AllianceBernstein L.P.
AllianceBernstein L.P.
5.88976%
T. Rowe Price Investment Management, Inc.
T. Rowe Price Investment Management, Inc.
3.32910%
BNP Paribas Asset Management USA, Inc.
BNP Paribas Asset Management USA, Inc.
...

Procept Biorobotics Executives and Management Board

HS

Mr. Hisham Shiblaq

(50)

Executive Vice President, Chief Commercial Officer

Compensation3.59 M USD
AN

Ms. Alaleh Nouri

(46)

Executive Vice President, Chief Legal Officer, Corporate Secretary

Compensation2.65 M USD
KW

Mr. Kevin Waters

(47)

Executive Vice President, Chief Financial Officer

Compensation2.19 M USD
LW

Mr. Larry Wood

(59)

President, Chief Executive Officer, Director · since 2024

Compensation537,421.00 USD
TP

Mr. Thomas Prescott

(69)

Independent Chairman of the Board

Compensation355,616.00 USD

Frequently asked questions about Procept Biorobotics

The business model of PROCEPT BioRobotics Corp. is focused on developing and commercializing innovative surgical technologies. The company specializes in the design and manufacturing of the AquaBeam® System, a robotic surgical platform used for treating patients with prostate conditions. This state-of-the-art technology combines the precision of a robotic arm with the benefits of water-jet technology to provide minimally invasive procedures with increased accuracy and efficiency. PROCEPT BioRobotics Corp. aims to improve patient outcomes by delivering advanced solutions in the field of urology through their AquaBeam® System, positioning themselves as leaders in robotic-assisted surgeries for prostate treatment.

All fundamentals and in-depth analysis of Procept Biorobotics

Our stock analysis for Procept Biorobotics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Procept Biorobotics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Procept Biorobotics Stock
Procept Biorobotics Revenue→
Procept Biorobotics Stock
Procept Biorobotics Net Income→
Procept Biorobotics Stock
Procept Biorobotics P/E→
Procept Biorobotics Stock
Procept Biorobotics P/S→
Procept Biorobotics Stock
Procept Biorobotics EBIT→
Procept Biorobotics Stock
Procept Biorobotics Dividend→
Procept Biorobotics Stock
Procept Biorobotics Directors Dealings→
Procept Biorobotics Stock
Procept Biorobotics Stocks→
Procept Biorobotics Stock
Procept Biorobotics Market capitalization→
Procept Biorobotics Stock
Procept Biorobotics Debt→
Procept Biorobotics Stock
Procept Biorobotics Liabilities→
Procept Biorobotics Stock
Procept Biorobotics Equity→
Procept Biorobotics Stock
Procept Biorobotics AAQS→
Procept Biorobotics Stock
Procept Biorobotics Employees→
Procept Biorobotics Stock
Procept Biorobotics ROE→
Procept Biorobotics Stock
Procept Biorobotics ROA→
Procept Biorobotics Stock
Procept Biorobotics ROCE→
Procept Biorobotics Stock
Procept Biorobotics News→
Procept Biorobotics Stock
Procept Biorobotics Analyst Price Targets→

Health Stocks

Processa PharmaceuticalsProbiotix HealthProcter & Gamble HealthPro-DexProcyonPro MedicusProdia Widyahusada Tbk PTPrivia Health GroupProfarma Distribuidora de Produtos FarmaceuticosPrivate Rented SectorProfessional Medical Expertise Company SJSCPRISM BioLab CoAll Stocks A–Z →